On Monday, Elevance Health Inc. (NYSE:ELV) received an Overweight rating from Morgan Stanley (NYSE:MS), accompanied by a price target set at $643.00. The rating reflects the firm's confidence in the company's diversified offerings and its ability to navigate regulatory and economic challenges.
The health services provider's stock is seen as resilient due to its balanced exposure to various segments, including the fast-growing Medicare Advantage, which accounts for 11% of its profit. Additionally, Elevance's Commercial and Exchange segments, which make up 34% and 3% respectively, along with Medicaid at 23%, provide a buffer against regulatory changes and economic cycles.
Morgan Stanley highlighted the potential in Elevance's efforts to scale its Pharmacy Benefit Management (PBM), Specialty Pharmacy, and Carelon Services. These areas are viewed as not fully appreciated by the market, despite their capacity to drive significant double-digit earnings growth in the future.
The firm's analysis suggests that Elevance is well-positioned to maintain strong performance, thanks to its strategic mix of services that cater to different market needs. This mix allows the company to withstand various pressures, from policy shifts affecting Medicare Advantage to fluctuations in employment that impact Commercial insurance dynamics.
Investors have responded positively to the new coverage, with expectations that Elevance's unique drivers and multiple growth levers will continue to support its financial health and stock performance in the long term. The Overweight rating indicates a bullish outlook for the company's shares, as Morgan Stanley projects robust earnings expansion ahead.
In other recent news, Elevance Health Inc has been the subject of several analyst reports. Mizuho Securities raised the stock's price target to $585 from $575, citing the company's recent performance and strategic partnerships. The firm also adjusted its adjusted earnings per share (EPS) estimates for Elevance for 2024 and 2025 by $0.10.
RBC Capital Markets also adjusted its stock price target for Elevance, increasing it to $575 from $574, due to the company's stronger guidance. Meanwhile, UBS raised its price target on shares of Elevance Health to $605 from $585, highlighting the company's recent elaboration on its collaborative care delivery relationship (CDR) partnership.
Wells Fargo (NYSE:WFC) raised the price target on Elevance Health Inc to $600 from $557 following the company's strong first-quarter results for 2024. The firm maintains an Overweight rating on the stock. Lastly, a Jefferies analyst slightly increased Elevance's price target from $602.00 to $604.00 and reiterated a Buy rating, noting the company's consistent conservative approach over the last two to three years.
InvestingPro Insights
As Elevance Health Inc. (NYSE:ELV) garners attention with its Overweight rating from Morgan Stanley, real-time data from InvestingPro enriches our understanding of the company's financial landscape. With a robust Market Cap of $124.21 billion and a Price to Earnings (P/E) Ratio standing at 20.06, Elevance shows substantial market presence and valuation. The company's revenue growth over the last twelve months as of Q1 2024 is notable at 6.89%, reflecting its operational success and potential for future expansion.
InvestingPro Tips for Elevance Health highlight the company's strategic financial moves, including an aggressive share buyback strategy and a commendable track record of raising its dividend for 13 consecutive years. This demonstrates a commitment to returning value to shareholders and a stable financial position. For investors seeking more insights, there are additional InvestingPro Tips available, providing a deeper dive into Elevance's market behavior and financial health. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to these valuable tips for a more informed investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.